A detailed history of Neo Ivy Capital Management transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Neo Ivy Capital Management holds 21,020 shares of BMRN stock, worth $1.38 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
21,020
Previous 904 2225.22%
Holding current value
$1.38 Million
Previous $74,000 1895.95%
% of portfolio
0.5%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$69.02 - $93.84 $1.39 Million - $1.89 Million
20,116 Added 2225.22%
21,020 $1.48 Million
Q2 2024

Jul 19, 2024

BUY
$74.43 - $92.22 $67,284 - $83,366
904 New
904 $74,000
Q3 2022

Nov 15, 2022

BUY
$82.16 - $96.94 $4,518 - $5,331
55 Added 7.4%
798 $68,000
Q2 2022

Aug 16, 2022

BUY
$71.48 - $86.85 $53,109 - $64,529
743 New
743 $61,000
Q4 2021

Feb 15, 2022

SELL
$71.72 - $91.47 $74,875 - $95,494
-1,044 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$74.77 - $85.47 $78,059 - $89,230
1,044 New
1,044 $129,000
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $38,132 - $42,818
-505 Closed
0 $0
Q1 2021

Oct 07, 2021

SELL
$74.73 - $90.69 $13,600 - $16,505
-182 Reduced 26.49%
505 $38,000
Q4 2020

Feb 16, 2021

BUY
$72.61 - $90.2 $49,883 - $61,967
687 New
687 $60,000
Q3 2020

Nov 17, 2020

SELL
$71.87 - $131.03 $253,485 - $462,142
-3,527 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$79.55 - $124.22 $197,522 - $308,438
2,483 Added 237.84%
3,527 $435,000
Q2 2020

Aug 17, 2020

BUY
$79.55 - $124.22 $54,730 - $85,463
688 Added 193.26%
1,044 $129,000
Q1 2020

May 15, 2020

BUY
$71.37 - $96.85 $25,407 - $34,478
356 New
356 $30,000
Q3 2019

Nov 21, 2019

SELL
$67.4 - $85.11 $237,719 - $300,182
-3,527 Closed
0 $0
Q2 2019

Aug 15, 2019

BUY
$80.35 - $93.9 $283,394 - $331,185
3,527 New
3,527 $302,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Neo Ivy Capital Management Portfolio

Follow Neo Ivy Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Neo Ivy Capital Management with notifications on news.